SCHEMBL388168

SCHEMBL388168

NC(=O)c1ccc(Cl)nc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 1/20 0.67
NNMT P40261 4/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
TDP1 Q9NUW8 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.50
KDM4E B2RXH2 1/20 0.50
DGAT1 O75907 1/20 0.50
SIRT6 Q8N6T7 1/20 0.50
RAB9A P51151 1/20 0.49
KCNQ3 O43525 2/20 0.47
KCNQ2 O43526 2/20 0.47
KCNE1 P15382 2/20 0.47
KCNQ1 P51787 2/20 0.47
ADRA2A P08913 1/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47
MDM4 O15151 1/20 0.46
TP53 P04637 1/20 0.46
MDM2 Q00987 1/20 0.46
EGFR P00533 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29524193 1.00 NAPRT (0.67) NAPRTNNMTSMN1; SMN2TDP1L3MBTL1
Hydrochloric Acid SCHEMBL3346497 0.98 NAPRT (0.64) NAPRTNNMTSMN1; SMN2TDP1L3MBTL1
Hydrochloric Acid SCHEMBL5013500 0.98 NAPRT (0.64) NAPRTNNMTSMN1; SMN2TDP1L3MBTL1
SCHEMBL11582144 0.91 NAPRT (0.56) NAPRTNNMTSMN1; SMN2TDP1L3MBTL1
SCHEMBL5013439 0.89 NAPRT (0.55) NAPRTNNMTSMN1; SMN2TDP1L3MBTL1
SCHEMBL5008264 0.89 NAPRT (0.55) NAPRTNNMTSMN1; SMN2TDP1L3MBTL1
Pyridine SCHEMBL28131297 0.88 NAPRT (0.58) NAPRTNNMTSMN1; SMN2TDP1L3MBTL1
2-Chloropyridine SCHEMBL7994540 0.88 SMN1; SMN2 (0.55) NAPRTNNMTSMN1; SMN2TDP1L3MBTL1
Niacinamide SCHEMBL15662857 0.86 F7 (0.71) NAPRTNNMTSMN1; SMN2TDP1SIRT6
SCHEMBL5075261 0.84 MKNK1 (0.66) NAPRTTDP1KCNQ3KCNQ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 817 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114213310-B Indoline compound and derivative thereof, preparation method, pharmaceutical composition and application 中国药科大学 2024-02-23 CN claimed
CN-117143014-A Lenvatinib derivative and preparation method and application thereof 深圳海王医药科技研究院有限公司 2023-12-01 CN claimed
CN-116891472-A Amide derivative containing imidazole structure, and preparation method and application thereof 延边大学 2023-10-17 CN claimed
CN-115536582-A Preparation method of medical intermediate 6-chloronicotinonitrile 浙江工业大学 2022-12-30 CN claimed
CN-114213310-A Indoline compound and derivative, preparation method, pharmaceutical composition and application thereof 中国药科大学 2022-03-22 CN claimed
US-20210338558-A1 USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN FABIUS BIOTECHNOLOGY (US) 2021-11-04 US claimed
CN-113046734-A Bivalent palladium complex solution and preparation method and application thereof 上海天承化学有限公司 2021-06-29 CN claimed
WO-2020068665-A1 USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN FABIUS BIOTECHNOLOGY (US) 2020-04-02 WO claimed
US-9884814-B2 Acylguanidines for treating osteoarthritis MERCK PATENT GMBH (DE) 2018-02-06 US claimed
US-20150361037-A1 ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-12-17 US claimed
WO-2004018428-A1 ANTIBACTERIAL BENZOIC ACID DERIVATIVES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 WO claimed
WO-2004018461-A2 ANTIBACTERIAL BENZOIC ACID DERIVATIVES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 WO claimed
CN-1447810-A Bicyclic pyrazoles with kinase inhibitor activity, process for their preparation and pharmaceutical compositions containing them PHARMACIA ITALIA SPA (IT) 2003-10-08 CN claimed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 WO claimed
US-5939568-A Accelerated catalysis of olefinic epoxidations THE SCRIPPS RESEARCH INSTITUTE (US) 1999-08-17 US claimed
WO-1998033786-A9 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS 1998-12-30 WO claimed
WO-1998033786-A1 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS THE SCRIPPS RESEARCH INSTITUTE (US) 1998-08-06 WO claimed
EP-0331052-A2 Process for the preparation of imidized acrylic polymers ELF ATOCHEM ITALIA S.r.l. (IT) 1989-09-06 EP claimed
EP-0315151-A2 Process for the preparation of imidized acrylic polymers ELF ATOCHEM ITALIA S.r.l. (IT) 1989-05-10 EP claimed
US-4141977-A Treatment of psoriasis with 6-substituted nicotinamides, 2-substituted pyrazinamides and closely related compounds YU RUEY J 1979-02-27 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210338558-A1 USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN COL14A1, COL2A1, COL1A1 NAPRT 2818/4885NNMT 4848/4885SMN1; SMN2 2228/4885
US-20150361037-A1 ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS CTSG, CTSD, CTSB NAPRT 3467/4885NNMT 2210/4885SMN1; SMN2 3634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.